Skip to main
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is a strong investment opportunity with a diverse market presence and an attractive position in both the clinical diagnostics and life sciences markets, with potential for accelerated sales growth and improved margins. The company also possesses valuable optionality through its 33% ownership stake in Sartorius, which is set to increase in value once the Sartorius Trust terminates in mid-2028. While there are risks associated with market recovery and potential share losses in specific areas, overall corporate governance and sustainability integration remain as the biggest concerns for investors. With a strong management team and potential for margin expansion, our outlook on Bio-Rad Laboratories remains positive.

Bears say

Bio-Rad Laboratories is experiencing significant restructuring and management changes, with recent targets of a mid-teens EBIT margin and potential improvements in sales growth through the lapping of headwinds. However, concerns remain over its ownership stake in Sartorius and limited sustainability integration. Investors should keep a close eye on the company's progress as the potential for increased optionality in mid-2028 could drive future value.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.